Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
ID: 353519Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353519

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-203.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for research focused on the neuropathological interactions between COVID-19 and Alzheimer’s disease-related dementias (ADRD). This initiative invites proposals for studies utilizing animal, cell culture, and human tissue models to investigate how COVID-19 affects cognitive decline in individuals with existing ADRD, accelerates ADRD pathology, and exacerbates neurological outcomes in those at risk. The funding opportunity aims to enhance understanding of the long-term neurological implications of COVID-19, with a total funding amount of up to $3.75 million available for up to five awards, each capped at $500,000 per year for a maximum of five years. Applications will be accepted starting September 4, 2024, with a final submission deadline of October 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-203-Full-Announcement.html
    PAR-24-203.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) for research investigating the neuropathological interactions between COVID-19 and Alzheimer’s disease-related dementias (ADRD). This initiative invites applicants to propose studies utilizing animal, cell culture, and human tissue models to explore mechanisms by which COVID-19 affects ADRD. Key objectives include examining how COVID-19 impacts cognitive decline in those already affected by ADRD, accelerates ADRD pathology, and exacerbates neurological outcomes in individuals with pre-existing ADRD. The funding opportunity is set to provide up to $3.75 million, supporting up to five awards, with budgets capped at $500,000 in direct costs per year for a maximum of five years. The application submission window opens on September 4, 2024, with a final deadline of October 5, 2024. Various organizations—including higher education institutions, nonprofits, and foreign entities—are eligible to apply, but clinical trials are not permitted under this initiative. The overarching aim is to advance understanding of the long-term neurological implications of COVID-19, contributing to public health knowledge and informing future interventions for ADRD.
    Similar Opportunities
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Investigations into Alzheimer’s Disease-Related Dementias (ADRD) Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)." This grant aims to support research that investigates the interactions of multiple co-pathologies associated with ADRD, focusing on their cellular and molecular mechanisms and their impact on cognitive and functional impairments. The initiative is part of a broader commitment to advance neuroscience research and address public health challenges related to dementia, with particular emphasis on studies that explore co-pathologies such as tau and alpha-synuclein. Interested applicants can apply for funding up to $500,000, with applications due by October 4, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html.
    Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries," aimed at fostering collaborative research on Alzheimer's disease (AD) and related dementias (ADRD) in low- and middle-income countries (LMICs). This initiative seeks to build sustainable neuroscience research capacity by encouraging partnerships between U.S. researchers and scientists from LMICs, focusing on population-relevant studies that address the unique epidemiological and risk factors associated with AD/ADRD in diverse populations. The program will provide a total of $2.16 million for up to five awards, with individual application budgets capped at $400,000 annually over a five-year period. Interested applicants must submit their proposals by February 14, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development and validation of human cellular models for Alzheimer's Disease-Related Dementias (ADRD) through the R01 Research Project Grant mechanism. This initiative aims to create novel and complex cellular models that accurately reflect the multifaceted pathologies and various cell types associated with ADRD, with a strong emphasis on validation against human data to ensure scientific rigor. The total funding commitment for this opportunity is anticipated to be up to $4.5 million for FY2025, with individual project budgets capped at $500,000 in direct costs annually for a maximum duration of five years. Interested applicants can find more details and guidelines in the full announcement available at NIH Grants, and inquiries can be directed to grantsinfo@nih.gov. The application deadline is October 21, 2024.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)" through a U01 cooperative agreement mechanism. This initiative aims to support the optimization of promising genome editing-based therapeutic leads for ADRD, focusing on preparing these candidates for Investigational New Drug (IND)-enabling studies. The funding is crucial for advancing research in various forms of ADRD, including Frontotemporal Dementia and Lewy Body Dementia, by refining therapeutic candidates to ensure their safety and efficacy. Interested applicants can apply for up to $1 million in funding, with a total budget commitment of up to $3 million per year for two awards, and must submit their applications by November 19, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings," aimed at enhancing the understanding of Alzheimer’s Disease Related Dementias (ADRD). This initiative focuses on utilizing structural biology methodologies to investigate the relationships between protein structures and clinical outcomes of ADRD, specifically seeking to generate structural information on proteins implicated in the disease within their native cellular environments. The NIH plans to allocate up to $3 million annually for up to four grants, with each grant not exceeding $500,000 per year for a maximum of five years, contingent upon funding availability. Interested applicants can submit their proposals starting September 4, 2024, with a submission deadline of October 5, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.